Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

611
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
611

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomimetic Nanogels Programmed for Irreversible-Electroporation-Primed Tumor Microenvironments to Elicit Durable Antitumor Immunity.

Biomaterials research·2026
Same author

Fucoidan-coated metal-organic framework nanoparticles for targeted delivery of nimodipine in subarachnoid hemorrhage-induced vasospasm.

Biomaterials science·2026
Same author

Development of a Sandwich-Type <i>sxtA4</i> Electrochemical Biosensor for Proactive Environmental Monitoring of STX-Producing Microalgae.

Biosensors·2026
Same author

Two-dimensional GeTe nanosheets for psoriasis through modulation of macrophage activation and psoriatic inflammation.

Biomaterials science·2026
Same author

Biomimetic lipid nanoparticles for macrophage reprogramming in cancer immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Resiquimod-loaded MOF525 enables synergistic photodynamic therapy and immunotherapy for colorectal cancer.

Nano convergence·2026
Same journal

In-Depth Analysis of AG73-Dental Pulp Cell Interactions Underlying Adhesion and Mineralization: Insights from Alanine Scanning.

Tissue engineering and regenerative medicine·2026
Same journal

Potentiated Maturation of hPSC-Derived Dopaminergic Neurons via Convergent Genetic and Small Molecule Modulation.

Tissue engineering and regenerative medicine·2026
Same journal

Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Diabetic β-Cell Apoptosis and Dedifferentiation by Delivering miR-4436.

Tissue engineering and regenerative medicine·2026
Same journal

Intratumoral Injectable Click-Crosslinked Hyaluronic Acid Depot for Sustained Gemcitabine Delivery.

Tissue engineering and regenerative medicine·2026
Same journal

Pressure-Regulated Chondrogenesis of BMSCs: Static Negative Pressure Primes Differentiation through Apoptotic Vesicles.

Tissue engineering and regenerative medicine·2026
Same journal

Differential Wound Healing Potential of Tonsil Parenchymal and Epithelial Mesenchymal Stromal Cell-Derived Exosomes.

Tissue engineering and regenerative medicine·2026
See all related articles

Related Experiment Video

Updated: Aug 8, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

702

Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.

Seungyong Shin1, Pyunghwajun Lee2, Jieun Han1,3

  • 1Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea.

Tissue Engineering and Regenerative Medicine
|March 3, 2023
PubMed
Summary
This summary is machine-generated.

Nanotechnology offers a novel approach to adoptive cell therapy, enhancing chimeric antigen receptor (CAR)-engineered immune cells for cancer treatment. This nanoparticle-based strategy aims to overcome limitations of traditional CAR-T cell therapy, particularly for solid tumors.

Keywords:
Cancer immunotherapyChimeric antigen receptor (CAR)Genetic engineeringImmune cell reprogramingNanoparticle

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

Related Experiment Videos

Last Updated: Aug 8, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

702
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

Area of Science:

  • Immunotherapy
  • Nanotechnology
  • Cellular Engineering

Background:

  • Chimeric antigen receptor (CAR)-engineered T cell (CAR-T) therapy shows promise for hematological cancers.
  • CAR-T therapy faces challenges including limited efficacy in solid tumors, complex procedures, and high manufacturing costs.

Purpose of the Study:

  • To introduce nanoparticle-based advanced CAR immune cell therapy.
  • To explore future perspectives on immune cell reprogramming using nanotechnology.

Main Methods:

  • Utilizing nanoparticles as a delivery platform for CAR engineering.
  • Applying nanotechnology to enhance CAR-T, CAR-natural killer, and CAR-macrophage therapies.

Main Results:

  • Nanoparticles offer unique physicochemical properties for targeted delivery and drug delivery.
  • Nanoparticle-based CAR therapy can be extended to natural killer and macrophage cells, addressing limitations of traditional CAR-T cells.

Conclusions:

  • Nanotechnology presents a promising alternative to conventional CAR-T cell therapy.
  • Nanoparticle-mediated immune cell reprogramming holds potential for improved cancer immunotherapy.